MICRO-RNAs OF NEUTROPHILS IN RENAL ANCA-ASSOCIATED VASCULITIS
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 63
- 试验地点
- 1
- 主要终点
- Expression profile of miRNAs in patients with AAV in circulating neutrophils, plasma and urine.
研究概览
简要总结
Activation of neutrophils by ANCA ("Anti-Neutrophil Cytoplasm Antibodies") and subsequent microvascular endothelial cell damage is the main feature of ANCA-associated vasculitis (AAV), a severe autoimmune disease that often targets the kidney. There is no specific treatment for AAV to date and 25% of patients with renal damage evolve towards end-stage renal disease, requiring dialysis and kidney transplantation. In addition, there is no reliable biological marker of the disease activity available, which makes the diagnostic, follow-up and treatment of patients difficult. Therefore, the identification of new therapeutic targets and non-invasive biomarkers constitutes a major clinical challenge to improve AAV patients care and to ameliorate their renal outcome.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •ANCA-associated vasculitis with Eosinophilic granulomatosis with polyangiitis (AAV-EGPA).
- •Infectious or progressive tumor pathology.
- •Pregnancy, lactation
- •Treatment with cyclophosphamide in the 6 months prior to inclusion.
- •Terminal chronic renal failure, presence of organ allograft.
- •Thrust Patients receiving corticosteroids> 20 mg / d in the previous 4 weeks.
- •Inability to give informed about information (subject in emergencies, understanding of the subject of difficulty, ...)
- •Minor subject, under judicial protection, guardianship
排除标准
- 未提供
结局指标
主要结局
Expression profile of miRNAs in patients with AAV in circulating neutrophils, plasma and urine.
时间窗: 6 month after maintenance treatment
次要结局
未报告次要终点